
Desmopressin (DDAVP) in the Treatment of Bleeding Disorders
This report reviews the spectrum of indications of desmopressin in the treatment of bleeding disorders.
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

This report reviews the spectrum of indications of desmopressin in the treatment of bleeding disorders.

Also Available In: Japanese Access to a comprehensive hemophilia treatment centre (HTC) is a critical component of care. This fact

A summary of discussions held at the World Federation of Hemophilia’s Global Forum on the Safety and Supply of Hemophilia

Presents data on the reported use of factor IX (FIX) per country. FIX use varies considerably, even among the wealthiest

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese 包括的血友病治療センター(HTC)は、ケアの極めて重要な要素です。このファクトシートでは、HTCがどのように設立され、それによって出血性疾患患者の全体的な健康および満足度がどのように向上するかを概説します。

Presents data on the reported use of factor VIII (FVIII) per country. FVIII use varies considerably, even among the wealthiest